4.4 Article

Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United States, March–August 2021

Related references

Note: Only part of the references are listed.
Article Immunology

Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccines for Preventing Coronavirus Disease 2019 Hospitalizations in the United States

Mark W. Tenforde et al.

Summary: From March to May 2021, full vaccination using authorized mRNA products was associated with 87.1% protection against COVID-19 hospitalization among US adults, with lower effectiveness in adults with immunosuppression compared to those without. Vaccination was beneficial for patients with immunosuppression, but the effectiveness was lower in this population.

CLINICAL INFECTIOUS DISEASES (2022)

Article Biochemistry & Molecular Biology

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

David S. Khoury et al.

Summary: The level of neutralizing antibodies is closely related to immune protection against COVID-19, playing a crucial role in protecting against detected infection and severe infection. Studies have shown that neutralizing titers will decline over time after vaccination, leading to decreased protection against SARS-CoV-2 infection.

NATURE MEDICINE (2021)

Article Public, Environmental & Occupational Health

Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults — United States, March–July 2021

Mark W. Tenforde et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)